CNTB

Connect Biopharma Holdings Limited

$0.68

1.79%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Source: Yahoo Finance

Market Cap$42.6M

Dividend Yield0.00%

AnalystsStrong Buy+767.5% target

Beta0.57

AI summary

Price & performance

1M-39.5%

3M-63.9%

YTD-68.3%

1Y-52.8%

52-week range—

Beta0.57

Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth50

Risk46

Performance57

Valuation27

Profitability19

Leverage45

Sentiment74

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$64K-99.8%

Net income-$55.5M

Net margin—

Historical fundamentals

Revenue exposure

Regions, segments, customers and suppliers

Valuation

CNTBIndustryP/E—85.07P/S14.4411.67EV/EBITDA—63.25P/B1.596.15PEG—2.86

Dividend yield0.00%

Every valuation metric

Historical Fundamentals

Revenue

Net Income

Net Margin

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q2 2026	vs a year before
Revenue	$64K	-99.8%	$2.8M	—
Net Income	-$55.5M	—	-$17.3M	—
Net Margin	—	—	-624.4%	—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 5639

Growth

Industry 7650

Risk

Industry 5546

Performance

Industry 6457

Valuation

Industry 2527

Profitability

Industry 4719

Leverage

Industry 6945

Sentiment

Industry 4874

Key Metrics

Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.770.37

Market Cap

42.6M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 633.9KSM 673.8K4M

Industry Market Share

0.00%

Sector Market Share

0.00%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 574 in the industry.

Company	Market cap	P/E	P/S	P/B	FCF yield	Implied growth	Revenue growth	ROE	Debt/equity
CNTBConnect Biopharma Holdings Limited	$42.6M	—	14.4	1.6	-142.2%	—	50.3%	-256.8%	0.0
ELTXElicio Therapeutics, Inc.	$42.5M	—	—	2.3	-87.1%	—	—	-189.6%	0.5
DWTXDogwood Therapeutics, Inc.	$42.4M	—	—	0.7	-38.8%	—	—	-39.3%	0.0
BMEABiomea Fusion, Inc.	$42.3M	—	—	5.6	-104.2%	—	—	-294.1%	0.0
PLRXPliant Therapeutics, Inc.	$43.2M	—	—	0.3	-154.6%	—	—	-71.4%	0.0
IMAImageneBio, Inc.	$43.2M	—	54.0	0.3	-94.0%	—	0.0%	-33.8%	0.0
TILInstil Bio, Inc.	$41.2M	—	—	0.4	-57.3%	—	—	-28.2%	0.0
IBOImpact BioMedical Inc.	$44.4M	27.5	—	4.4	0.3%	46.8%	—	15.9%	0.0
HBP.TOHelix BioPharma Corp.	$45.5M	—	—	4.6	-6.6%	—	—	-23.6%	0.3
Industry median		13.2	7.1	2.1	-23.9%	9.7%	12.8%	-60.6%	0.0
CNTB percentile		—	65th	39th	16th	—	69th	12th	39th